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be effective in treating a highly prevalent, costly, and asymptomatic condition such as 
hypertension.
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OUTPATIENTS IN SOUTHERN TAIWAN
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OBJECTIVES: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin 
receptor blockers (ARBs) have substantially contributed to the escalating antihyper-
tensive drug cost in Taiwan. Increasing literature has proposed potential beneﬁts of 
combing ACEIs/ARBs in controlling blood pressure, but there is still a lack of evidence 
to support the rationale of ACEIs/ARBs combination in treating hypertension. This 
study aims to explore the current utilization and prescribing patterns of ACEIs/ARBs 
combination in Taiwan. METHODS: A cross-sectional study was conducted from 
2006 to 2008, using a regional reimbursement claim database from the KaoPing Divi-
sion of National Health Insurance. Individual data of hypertensive outpatients treated 
with ACEIs or ARBs for more than 28 days per year in Southern Taiwan were 
extracted. Demographic and prescribing data were collected, and then descriptive 
analyses were used to evaluate patients’ characteristics and prescribing patterns of 
ACEIs, ARBs and their combination. Wald chi-square tests and Student’s t-test were 
conducted to examine the prescribing associated variables and differences between 
health care facilities. RESULTS: During the 3-year study period, 4,482,826 prescrip-
tions were assessed, including 44.69% (n = 2,003,278) ACEIs and 55.31% (n = 
2,479,548) ARBs prescriptions. Of all, 1.22% (n = 54,526) prescriptions have either 
doubled or combined more than one ACEI. Likewise, 2.29% (n = 102,486) have 
doubled or combined ARBs. Furthermore, 0.61% (n = 27,381) prescriptions combined 
both ACEIs and ARBs. The majority of these combinations were prescribed in medical 
centers in continuous prescriptions for long-term reﬁlls, and the amount of combined 
prescriptions increased annually. The major co-morbidity of ACEIs/ARBs combina-
tions is diabetes mellitus (n = 9871, 36.05%), and chronic renal disease (n = 5055, 
18.46%) and congestive heart failure (n = 886, 3.24%). CONCLUSIONS: We found 
a small proportion of ACEIs/ARBs combination, yet the combined prescriptions are 
increasing and used chronically in patients with speciﬁc co-morbidities. Further studies 
are needed to explore the effectiveness and rationality of this combination.
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OBJECTIVES: Upon the coverage limitations proposed by Taiwan National Health 
Insurance (NHI), the dual therapy with clopidogrel and aspirin would be reimbursed 
up to 9 months for speciﬁc indications since 2004. Although evidence showed its risks 
outweighed the beneﬁts comparing to use aspirin alone, it is a lack of study examining 
population use of dual therapy. A secondary data analysis was performed to examine 
the use patterns of dual antiplatelet therapy (DAT), speciﬁcally among older adults in 
Taiwan. METHODS: A population-based longitudinal assessment was conducted 
using the 2003–2007 NHI databases. Those beneﬁciaries in 60 years old of age and 
greater during the study period were evaluated. All relevant data, including visits 
toward physician clinics, outpatient departments, use of medications, and pertinent 
coverage cost in the datasets of ambulatory care were retrieved and analyzed. Descrip-
tive analysis was performed to describe and compare the utilization of DAT for less 
or greater than 3 months (shorter vs. longer treatment). RESULTS: Of half million 
beneﬁciaries being evaluated, 1099 patients were prescribed DAT. Of which, 71% 
were older adults (age = 71 ± 7.8 years old). There was a sharply increasing utilization 
of DAT in 2007 for a total of 785 older patients. 85% were prescribed with approval 
indications (i.e., ischemic heart diseases) for aspirin or clopidogrel alone. 29.8% pos-
sessed with at least one atherothrombotic risk factors (DM, dyslipidemia), which 
might attribute to DAT. The duration of DAT was up to 13 months. The total drug 
expenses were 66% and 85% among shorter and longer treatment patients, respec-
tively. The cost of DAT accounted for up to 51% of total drug expense. CONCLU-
SIONS: There were sharply increasing utilization of DAT among Taiwanese older 
adults since 2007. Further studies are needed to explore the contributing factors of 
DAT and its effectiveness and safety outcomes.
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OBJECTIVES: The prevalence of hypertension is increasing in epidemic proportions 
in the Indian subcontinent. Despite the well known beneﬁts of aggressive blood pres-
sure control in hypertensive patients, data from the subcontinent indicate that the 
control of hypertension remains remarkably poor. Our previous study demonstrated 
that calcium channel blockers (CCBs) were the most prescribed agents for uncompli-
cated hypertension in three South Indian Hospitals. The objective of this study was 
to assess the physician’s perspectives with regard to antihypertensive pharmacotherapy 
and to determine whether they are in accordance to national and/or international 
hypertension guidelines. METHODS: A questionnaire was developed containing ques-
tions on familiarity with guidelines, diagnosis of clinical hypertension, and evaluation 
of patients with hypertension with or without co-morbidities, treatment of hyperten-
sion including choice of drugs, and drug regimens or speciﬁc drug combinations. The 
questionnaire was administered to interns and physicians of Medicine Department of 
three teaching-hospitals in South India. RESULTS: Among a total of 57 physicians 
who received the survey 58.1% expressed familiarity with the JNC-VII guidelines 
whereas 12.8% were familiar with the Indian Hypertension Guidelines-II. Although 
majority of the physicians were aware of the guidelines about 37% of them indicated 
that they would prefer CCBs as the ﬁrst drug for treating uncomplicated hypertension. 
When asked about monotherapy versus combination therapy a majority (91.2%) of 
the physicians chose a two-drug combination over monotherapy. CCB with ACE-
inhibitors was the most favored choice followed by combinations of CCBs with 
beta-blockers and diuretics. CONCLUSIONS: The physician’s preference of CCBs and 
combination therapy over other antihypertensives and monotherapy may be attributed 
to the better treatment outcomes they experienced and is consistent with emerging 
trends observed in recent studies such the ACCOMPLISH and ASCOT trials that 
underscore the beneﬁts of using combination therapy with CCBs as initial therapy for 
hypertension.
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OBJECTIVES: This study evaluates changes in utilization patterns of class I (ﬂecainide 
and propafenone) and class III (amiodarone) antiarrhythmics in France, Italy, Spain, 
Germany, and the UK from 2005 to 2009. These drugs are used for treatment of 
supraventricular and ventricular arrhythmias of which atrial ﬁbrillation is the most 
common among the adult population. METHODS: Utilization trends were examined 
using IMS Market Trend Analysis, a database of global sales from all corporations 
with pharmaceutical products sold into a pharmacy or hospital as well as prescription 
information from ofﬁce-based physicians. Utilization of antiarrhythmic drugs was 
assessed using patient days of therapy (PDoT). Descriptive analyses were conducted 
for speciﬁc drug classes as well as individual agents, including ﬂecainide, propafenone, 
and amiodarone. RESULTS: Overall, PDoT was highest for amiodarone, the main 
representative class III agent, with an average of 229 million PDoT over the ﬁve year 
period across all markets. During this time, PDoT for amiodarone increased by 9.5% 
in Italy (50.9 to 55.7 million), 13.8% in Germany (32.9 to 37.5 million), and 0.5% 
in France (85.8 to 86.3 million) and decreased by 20.6% in the UK (32.8 to 26.0 
million) and 2.5% in Spain (27.2 to 26.5 million). This resulted in greater class III 
drug use in all markets except Italy, where class I agents were preferred over class III 
agents consistently from 2005 to 2009. Among all antiarrhythmics, ﬂecainide showed 
a consistent overall increase in PDoT over the study period, with a 22.4% increase 
from 110 to 135 million PDoT and a resulting increase in market share from 24% to 
29.4% from 2005 to 2009. CONCLUSIONS: Amiodarone was the dominant antiar-
rhythmic in all markets. However, increases in ﬂecainide use in 4 out of 5 European 
markets suggest a possible change in rhythm control strategy for the treatment and/
or management of arrhythmias.
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OBJECTIVES: In January 2009, an authorization form was implemented which 
required Dutch clinicians to justify the prescription of branded statins, leading to 
signiﬁcant switching of patients from atorvastatin to generic simvastatin. However, 
current prescription data indicates that much of this switching is occurring at less than 
equipotent doses. We sought to assess the potential consequences in terms of cardio-
vascular disease. METHODS: Data from a pharmacy database covering the majority 
of drug dispenses in the The Netherlands informed dose-speciﬁc patterns of switching 
from atorvastatin to generic simvastatin. Dose-speciﬁc, LDL-C-modifying potencies of 
the two statins were derived from a recently-published meta-analysis. The relationship 
between reduction in LDL-C achieved by statin therapy and relative reduction in risk 
of coronary and stroke risk was derived from a recently-published meta-regression. 
This showed that for every 0.65 mmol/L (25 mg/dL) reduction in LDL-C, the relative 
risk (RR) (95% conﬁdence interval [CI]) for a coronary and stroke event were 0.84 
(95%CI 0.82–0.86) and 0.90 (95%CI 0.86–0.94), respectively. RESULTS: Out of the 
39,031 Dutch patients who were switched from atorvastatin to generic simvastatin in 
the ﬁrst quarter of 2009, 33.7%, 47.2% and 19.1% were switched to less potent, 
equipotent and more potent doses of simvastatin, respectively. The net (weighted-
average) effect would have been a 5.6% increase in LDL-C. Assuming a baseline 
LDL-C of 2.5 mmol/L (98 mg/dL), the predicted relative increases (95%CI) in the 
risks of coronary and stroke events were 3.4% (3.0–3.9%) and 2.1% (1.3–3.0%), 
respectively. The equivalent ﬁgures for a baseline LDL-C of 3.0 mmol/L (117 mg/dL) 
were 4.1% (3.6–4.6%) and 2.6% (1.5–3.6%), and for a baseline LDL-C of 3.5 mmol/L 
(137 mg/dL), they were 4.8% (4.2–5.4%) and 3.0% (1.8–4.2%). CONCLUSIONS: 
